- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Keiichi Fujiwara
Medical Oncologist, Saitama Medical University, Saitama, Japan
If BIBF 1120* has been approved by the regulatory authorities it will provide large benefit on the ovarian cancer patients: 60 – 70% of those women, diagnosed, newly diagnosed as ovarian cancer patients, is found on the stages of three or four, and the five-year survival rate of those stages is about 30-40% - so very, very poor prognosis this is. So, we really need some new strategies to improve the poor patients’ prognosis.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
